NCT06455605View on ClinicalTrials.gov

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

PHASE1RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2030

Conditions
Recurrent Glioblastoma IDH Wildtype
Interventions
DRUG

D2C7-IT

D2C7-IT will be dosed at 166,075 ng in 36 mL.

DRUG

2141 V11

2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Darell Bigner

OTHER